Flurbiprofen 8.75mg lozenges sugar free

PurposeOur objective was to update and organize information about the safety of using nonsteroidal anti-inflammatory drugs (NSAIDs) during lactation and assess whether the available information in the prescribing information (PI) of the approved drugs allows a health care professional to orient a lactating woman whether to use the drug.MethodsFor this systematic review, we searched MEDLINE, Embase, Cochrane, and LILACS for published articles from inception to 2024, reviewed the PI, and collected risk classifications for use during lactation for 23 NSAIDs from 5 widely available sources. No language restrictions were placed on the search. Data were synthesized, and the risk of bias and certainty of evidence were analyzed. A protocol was registered on the PROSPERO database (CRD42022295292).FindingsWe identified 3327 articles, removed 292 duplicates, and, after screening, retained 34 studies examining NSAID and acetaminophen excretion in breast milk and neonatal safety outcomes. Ten studies revealed acetaminophen, ibuprofen, flurbiprofen, mesalazine, and dipyrone adverse effects in infants. The relative infant dose was usually below 10%. Pharmacokinetic reasoning indicated that the infant must drink more milk than 150 ml/kg/d to reach the pediatric-approved dose. Only five PI of 16 NSAIDs approved in all jurisdictions had adequate information for decision making. The lists classifying the risks of drug use during lactation usually agree; however, they occasionally differ with the PI and each other, making it difficult to interpret.ImplicationsDespite recent efforts to adequate labeling, NSAIDs still lack enough data to establish whether lactating women should use them.

Abstract licence: CC BY

BackgroundThe optimal analgesic regimen after video-assisted thoracoscopic surgery (VATS) is unclear. We aimed to examine whether ultrasound-guided serratus anterior plane block (SAPB) with liposomal bupivacaine could provide continuous and effective analgesic effects for lung cancer patients undergoing VATS.MethodsA total of 64 patients were randomly allocated to receive either the liposomal bupivacaine (LB group) or the ropivacaine (RO group). The primary outcome was pain score at rest and on movement in the first three days after surgery. The secondary outcomes included intraoperative remifentanil consumption, perioperative consumption of sufentanil and flurbiprofen axetil, time to extubation, time to first bowel movement, time to first flatus, incidence of postoperative nausea and vomiting (PONV), length of intensive care unit (ICU) stay, length of hospital stay, hospitalization costs, and early recovery quality as assessed by QoR-15 score.ResultsThe LB group had significantly lower pain scores at rest and on movement at 12h, 24h, 36h, 48h, and 72h after surgery, and lower pain scores on movement at 8h after surgery, when compared with the RO group. Perioperative sufentanil consumption and postoperative flurbiprofen axetil consumption were significantly reduced in the LB group than in the RO group. In addition, compared with the RO group, the LB group had earlier first flatus, mobilization, and urinary catheter removal, shorter ICU stay, lower incidence of PONV, and lower hospitalization costs. The QoR-15 scores in the first three days after surgery were significantly higher in the LB group than in the RO group. There were no statistically significant differences between the two groups regarding time to extubation, intraoperative remifentanil consumption, and length of hospital stay.ConclusionUltrasound-guided SAPB with liposomal bupivacaine was effective in relieving postoperative pain for three days after surgery in patients undergoing VATS.

Abstract licence: CC BY-NC

BackgroundTotal knee arthroplasty (TKA) poses a significant challenge for acute pain. Opioid-based analgesia carries substantial risks, whereas non-steroidal anti-inflammatory drugs (NSAIDs) have adverse effects and ceiling effects. Ulinastatin may be a novel treatment option with improved efficacy and safety.PurposeTo compare the efficacy and safety of single preoperative administration of ulinastatin (UTI), flurbiprofen axetil (FA), and control (saline) in reducing opioid consumption and adverse events in TKA.Patients and methodsIn this prospective, double-blind, placebo-controlled trial, 150 TKA patients were randomized to receive intravenous UTI (30 IU), FA (100 mg), or saline 15 minutes before skin incision. Standardized postoperative analgesia utilizes patient-controlled intravenous analgesia (PCIA) to maintain visual analog scale (VAS) scores ≤30 mm. The primary outcome was cumulative morphine consumption within 72 h postoperatively, while the secondary outcomes included adverse reactions and inflammatory factor levels (IL-6 and IL-10).ResultsThe final analysis included 149 patients. Median 72-hour morphine consumption was significantly lower with UTI (29.00 [22.50-33.50] mg) than with FA (40.00 [27.50-60.50] mg) and the control (54.40 [46.40-82.80] mg, P P > 0.05). UTI reduced total adverse reactions (24.5%) versus FA (48.0%, P = 0.015) and control (52.0%, P = 0.005), specifically lowering vomiting (4.1 vs 20.0%), gastrointestinal discomfort (6.1 vs 26.0%), and delirium (4.1 vs 30.0%). UTI suppressed IL-6 and IL-10 elevation better than control (ΔIL-6:0.00 vs 1.63 pg/mL, P = 0.003; ΔIL-10:2.20 vs 19.92 pg/mL, P ConclusionSingle preoperative UTI significantly reduced postoperative morphine consumption (~48%) and adverse reaction risks compared with FA and control by modulating the balance of proinflammatory and anti-inflammatory factors (IL-6 and IL-10). UTI provides an efficient and safe alternative, supporting its inclusion in enhanced recovery after surgery (ERAS) analgesia strategies.

Abstract licence: CC BY-NC